Portfolio & Assets
The gap
Classical averages miss real biology
Patients are biologically heterogeneous. Linear statistics often hide non-linear, multi-factorial treatment effects – leading to ‘inconclusive’ trials that overlook true responders.
Underpowered
subgroups
Small responder groups are dismissed as noise, undermining promising therapies.
Heterogeneous
patients
patients
Variability in genetics and biochemical processes influences clinical data outcomes and can materially impact trial results.
Rigid trial
designs
designs
Static protocols can’t adjust as biology reveals itself during the study.
The platform
From averages to biological understanding
CliniQuantum aims to unify data enrichment with quantum modeling (advanced and innovative mathematical approaches using quantum‑based algorithms) and adaptive trial guidance – so every data point counts.
Data
Enrichment
Integrates biological markers, clinical endpoints, and mechanistic context into harmonized, quantum‑ready datasets.
Quantum
Modeling
Advanced and innovative mathematical approaches using quantum‑based algorithms explore complex probability landscapes to reveal latent responder clusters and mechanisms.
Adaptive Trial
Optimization
Translate insight into action – refine inclusion, dosing, arms, and endpoints as molecular signals emerge.
Workflow
How it works
From raw signals to adaptive, mechanism‑guided decisions.
Enrich the data
Unify clinical outcomes with biological‑marker layers; align preclinical and human evidence.
Translate to quantum
Convert continuous biological signals into energy‑landscape representations suitable for quantum exploration.
Model & discover
Apply advanced mathematical models and quantum-based algorithms to identify responder clusters, mechanisms, and efficacy and toxicity signals.
Adapt the trial
Recommend inclusion, dosing, arms, and endpoint refinements; simulate impact pre‑amendment.
Applications
Where we aim to create value
Preclinical → Phase III → Post‑market: unified analytics across the development lifecycle.
01
Preclinical / Translational
Cross‑species signature alignment and mechanism mappingBiomarker hypothesis generation and dose/PK‑PD bridgingModel selection informed by translational evidence02
Early Clinical (Ph I/II)
esponder/non‑responder discoverydaptive design support and endpoint refinementSafety signal triage via molecular correlates03
Late Clinical (Ph III)
Inconclusive‑trial forensics and stratified analysesMarker‑guided enrichment and synthetic controlsMechanism‑anchored evidence for filings and labeling04
